等待开盘 11-18 09:30:00 美东时间
-0.035
-8.94%
Outlook Therapeutics appoints Greg DiPasquale as Chief Commercial Officer to lead the U.S. launch of LYTENAVA™, the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD. With over 30 years of experience in eye care and multiple retina product launches, including BEOVU®, EYLEA® and EYLEA® HD, DiPasquale will oversee commercialization efforts, including market access, marketing, sales, and reimbursement. LYTENAVA is expected to be a...
10-09 12:30
Outlook Therapeutics submitted an application to CMS for a permanent, product-specific HCPCS Level II J-code for LYTENAVA, aiming to streamline billing and improve market access for its FDA-approved treatment of wet age-related macular degeneration (wet AMD). The company remains on track for a U.S. commercial launch before year-end 2026. LYTENAVA is a recombinant humanized IgG1 monoclonal antibody targeting VEGF-A, with potential risks including ...
10-01 13:01
Outlook Therapeutics ( ($OTLK) ) has issued an update. On September 25, 2026, O...
10-01 05:00
Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On September 16,...
09-19 05:20
今日重点评级关注:Ascendiant Capital:维持Outlook Therapeutics"买入"评级,目标价从10美元升至10.5美元;摩根士丹利:维持Aurora Innovation"超配"评级,目标价从14美元升至18美元
09-14 16:05
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
09-11 18:04
Outlook Therapeutics announced the availability of a pre-recorded fireside chat from the H.C. Wainwright Global Investment Conference, featuring CEO Bob Jahr and analyst Douglas Tsao discussing the company's recent developments. The chat is now available on-demand via the company's website. The Conference will be held September 14-16, 2026, in New York, with management available for one-on-one meetings. Outlook Therapeutics focuses on LYTENAVA, a...
09-11 11:00
Outlook Therapeutics announced CEO Bob Jahr's participation in a Virtual Investor CEO Connect segment discussing the FDA approval of LYTENAVA, the first FDA-approved ophthalmic bevacizumab for wet AMD. The company plans a U.S. launch by year-end 2026, targeting over $500 million in annual sales by 2030. LYTENAVA is already commercialized in Europe and the UK. The drug works by inhibiting VEGF, reducing vision loss. Key safety concerns include int...
09-10 13:10
Outlook Therapeutics appoints Kevin Lundquist as Chief Financial Officer, effective September 1, 2026. Lundquist, with over 20 years of experience in finance and operations across pharmaceutical and medical technology industries, will help build financial and operational infrastructure for the U.S. commercial launch of LYTENAVA™ following its FDA approval. He previously served as CFO at CapsoVision, Inc., leading its IPO, and has extensive experi...
08-27 20:05
Outlook Therapeutics' CEO Bob Jahr highlighted the company's transformative period following FDA approval of LYTENAVA™, the only FDA-approved ophthalmic bevacizumab for wet AMD in the U.S. During the Virtual Investor "Why Now" conference, Jahr discussed the transition from development to commercial stages, U.S. launch preparations, European presence, and potential to redefine retinal care standards. The webcast is available on-demand.
08-27 13:01